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Abstract
Background: Animal models of human diseases are essential as they allow analysis of the disease process at the
cellular level and can advance therapeutics by serving as a tool for drug screening and target validation. Here we
report the development of a complete genetic model of spinal muscular atrophy (SMA) in the vertebrate zebrafish
to complement existing zebrafish, mouse, and invertebrate models and show its utility for testing compounds that
alter SMN2 splicing.
Results: The human motoneuron disease SMA is caused by low levels, as opposed to a complete absence, of the
survival motor neuron protein (SMN). To generate a true model of SMA in zebrafish, we have generated a
transgenic zebrafish expressing the human SMN2 gene (hSMN2), which produces only a low amount of full-length
SMN, and crossed this onto the smn
-/- background. We show that human SMN2 is spliced in zebrafish as it is in
humans and makes low levels of SMN protein. Moreover, we show that an antisense oligonucleotide that
enhances correct hSMN2 splicing increases full-length hSMN RNA in this model. When we placed this transgene on
the smn mutant background it rescued the neuromuscular presynaptic SV2 defect that occurs in smn mutants and
increased their survival.
Conclusions: We have generated a transgenic fish carrying the human hSMN2 gene. This gene is spliced in fish as
it is in humans and mice suggesting a conserved splicing mechanism in these vertebrates. Moreover, antisense
targeting of an intronic splicing silencer site increased the amount of full length SMN generated from this
transgene. Having this transgene on the smn mutant fish rescued the presynaptic defect and increased survival.
This model of zebrafish SMA has all of the components of human SMA and can thus be used to understand
motoneuron dysfunction in SMA, can be used as an vivo test for drugs or antisense approaches that increase full-
length SMN, and can be developed for drug screening.
Introduction
Identification of the survival motoneuron gene (SMN) as
the genetic cause of the motoneuron disease spinal mus-
cular atrophy (SMA) [1] was a major advance in the
motoneuron disease field. It has enabled a way to model
the disease in animals as a means to study disease biol-
ogy and develop therapeutics. The genetics of SMA has
been well characterized and supports that SMA arises
from a deletion of the SMN1 gene and reliance for pro-
duction of the SMN protein from the SMN2 gene [2-4].
The SMN2 gene, however, carries a number of nucleo-
tide differences compared to SMN1 and one of these at
position 6 in exon 7 results in a silent mutation that
changes the splicing pattern of the gene [5,6]. The result
is that the vast majority (~80-90%) of SMN from the
SMN2 gene lacks exon 7 (SMNΔ7) [1]. This yields an
unstable protein that cannot substitute for the full-
length SMN protein [6-8].
Based on this information, an animal model of SMA
needs both a deletion/dysfunction of the SMN1 gene
and the presence of the SMN2 gene. An evolutionary
analysis revealed that the SMN1 gene is duplicated in
the chimpanzee genome, but only humans have the
SMN2 gene [9]. Thus, it has been hypothesized that the
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SMN1 a l l e l e s .S i n c eo n l yh u m a n sh a v et h eSMN2 gene,
the best way to generate an animal model of SMA is to
add the hSMN2 as a transgene to an animal with a
deleted/mutated SMN1. To date, this has been done in
mice to generate a number of important models of
SMA [2,3,7,10]. Models of SMA in drosophila, zebrafish,
and Xenopus have relied on maternal Smn contributions
[11,12] or transient Smn knockdown [13,14]. While
these models are useful, they often have Smn levels that
change during development and may not fully recapitu-
late the disease. To generate a complete model of SMA
in zebrafish, we have generated transgenic zebrafish
expressing the hSMN2 gene with its endogenous promo-
ter. We then crossed this transgene into the previously
characterized smnY262stop
-/+ l i n e[ 1 2 ] .H e r ew es h o w
that hSMN2 is spliced in zebrafish consistent with what
is seen in humans and mice [3]. In addition, we show
that disrupting an intronic splicing silencer can increase
the levels of full-length SMN from this transgene. The
presence of the transgene results in a modest increase
in SMN protein, a modest increase in survival compared
to mutants lacking the transgene, and a delay in the pre-
synaptic defect seen in smn mutant fish. Together these
data show that we have generated a zebrafish model of
SMA that has the genetics of human SMA.
Results
Characterization of transgenic hSMN2 zebrafish lines
To generate a complete model of SMA in zebrafish, we
generated a transgenic zebrafish line expressing hSMN2.
It had previously been shown that the entire human
hSMN2 gene including its promoter was on a 35.5 kb
BamHI fragment in the genomic clone PAC 215P15 [3].
Recombineering [15] was used to clone the BamHI frag-
ment out of PAC 215P15 and tag the DNA with a 0.6
kb fragment of the zebrafish heat shock 70 promoter
(0.6hsp70)[ 1 6 ]d r i v i n gD s R e di n t op I n d i g o B a c 5 .T h e
hsp70:DsRed component was used for screening trans-
genics (Figure 1). The total construct therefore was Tg
(hSMN2;0.6hsp70:DsRed), hereafter referred to as Tg
(hSMN2). This DNA construct was microinjected into
early one-cell stage embryos. To determine which
embryos received a high amount of DNA, injected
embryos were heat shocked (37°C for 30 minutes) at 24
hours post fertilization (hpf). Only embryos expressing
ubiquitous DsRed were grown for transgenic lines
(~0.3-0.5%) thus increasing the chance of these fish hav-
ing incorporated DNA into their germline. After inject-
ing and screening, 38 F0s were grown to adulthood (~3
months) and then outcrossed to generate F1s. All F1s
were heat shocked and those showing DsRed expression,
indicative of the transgene, were grown to adulthood
(Figure 1C). Approximately, 3% of the F0s gave rise to
transgenic F1s. To examine Tg(hSMN2)e x p r e s s i o n ,
RNA obtained from 24 hpf transgenic embryos was
used for RT PCR. hSMN2 was expressed in 10 trans-
genic zebrafish lines and 3 lines (os38, os39, os40)
showed correct splicing of the hSMN2 gene (Figure 2).
T h e s es p l i c ep r o d u c t sw e r ec haracterized by both size
and sequence. All three splice products, transcripts lack-
ing exon 7 (Δ7), transcripts lacking exon 5 (Δ5), and
transcripts lacking both (Δ5, Δ7) were present in all
three lines. The splicing pattern was similar to the spli-
cing pattern for endogenous hSMN2 from transgenic
mice with low and high hSMN2 copy number [3] and
from a human cell line (Figure 2A). The Δ7a n dΔ5
forms were consistently present in these transgenic
Figure 1 Strategy for generating Tg(hSMN2) zebrafish.
(A) Diagrammatic representation of the hSMN2:0.6hsp70:DsRed DNA
construct. Arrows indicate the direction of expression. (B) Digestion
of the hSMN2:0.6hsp70:DsRed construct using BamHI on 0.5%
agarose gel. Lane 1, high molecular weight DNA ladder (Invitrogen);
lane 2-3, two examples of the hSMN2:0.6hsp70:DsRed construct.
(C) Transgenic larvae (3 dpf) as revealed by heat shocking.
Figure 2 Expression of hSMN2 RNA in transgenic zebrafish.
Representative polyacrylamide gel showing RT-PCR product from
hSMN2 RNA in transgenic lines. Lane 1, 1 kb DNA ladder. Lane 2,
negative control from a wild-type nontransgenic fish. Lanes 3 and 4,
samples from spinal cords of low and high SMN2 copy transgenic
mice [3], respectively. Lanes 5-10, single 3 dpf Tg(hSMN2)os38 larva.
Lanes 11-13, single 3 dpf Tg(hSMN2)os39 larva. Lane 14, single 3 dpf
Tg(hSMN2)os40 larva. Lane 15, human breast cancer cell line as a
control.
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gene copy number was estimated by quantitative PCR
from DNA isolated from fin tissue. Hemizygous fish
from Tg(hSMN2)os38, Tg(hSMN2)os39, and Tg(hSMN2)
os40 had 30, 4, and 16 transgene copies respectively.
RNA analysis from Tg(hSMN2)os38 revealed that full-
length hSMN RNA is expressed as early as 6 hpf with
an increase in the full-length hSMN between 6 and 24
hpf (Figure 3).
Blocking an intronic splicing silencer site results in more
full-length hSMN in Tg(hSMN2) fish
An important therapeutic approach to SMA is to find
methods to increase the amount of full-length SMN
generated from the SMN2 gene. One promising
approach that has recently been tested in vivo is to use
antisense oligonucleotides against an intronic splicing
silencer (ISS) site in intron 7 [17] to increase exon 7
inclusion and thus generate more full-length SMN from
the SMN2 g e n e[ 1 8 ] .T ot e s tw h e t h e rt h eTg(hSMN2)
zebrafish could be used as a tool to test this technology,
we injected an antisense ISS-NI morpholino (MO) into
1-cell stage Tg(hSMN2)os38 embryos. At 3 days post fer-
tilization (dpf) RNA was harvested and the human SMN
full-length and SMNΔ7 levels generated from the trans-
gene were analyzed by RT-PCR and quantified by mea-
suring band intensity (Figure 4). Uninjected embryos
had a full-length SMN/SMNΔ7 ratio of 0.36 ± 0.05
(mean ± sd). When we injected 9 ng of ISS-NI MO, the
ratio increased ~5-fold to 1.9 ± 0.13 and the ratio
increased ~10-fold (3.45 ± 0.54) with the 15 ng dose.
When we injected the highest dose, 18 ng, the ratio
increased ~7-fold (2.9 ± 0.34) however the embryos
showed some developmental abnormalities suggesting
that this dose was too high. This increase was transient,
however, and was no longer present at 7 dpf (data not
shown). This is not surprising since morpholino perdur-
ance is variable and most reports indicate early pheno-
types within 3-5 dpf [19]; although each morpholino is
unique and some can affect protein levels into the sec-
ond week of development [13]. These data show that Tg
(hSMN2) zebrafish respond to splicing factors similarly
to mice carrying the human transgene and can serve as
a fast and easy in vivo system to test approaches to
increase full-length SMN from the hSMN2 gene.
We next asked whether this change in splicing
increased the amount of full-length protein generated
from the transgene. For this we used a human specific
SMN antibody [18]. To determine whether hSMN was
being made from the transgene, we first analyzed 3 dpf
Tg(hSMN2)os38 and found that hSMN was present at
low levels (Figure 5). Next, we analyzed protein from 3
dpf Tg(hSMN2)os38 larvae injected with ISS-N1 MO at
the 1-2 cell stage. Here we found an ~ 3-fold increase
in hSMN protein. These data show that hSMN is made
in Tg(hSMN2) and disrupting a splicing motif can
increase the levels.
Figure 3 Expression of hSMN2 RNA during embryonic
development in transgenic zebrafish. (A)Representative
polyacrylamide gel showing RT-PCR product obtained from Tg
(hSMN2)os38 RNA during early development. RNA from three
embryos was prepared at 3, 6, 12, 24, and 72 hpf. Lane 1, 1 kb DNA
ladder. Human, RNA from a human breast cancer cell line.
(B) Quantification of the ratio of full-length hSMN/hSMNΔ7 from
three separate experiments shown as mean ± sd.
Figure 4 Disrupting an intronic splice silencer site increases
the amount of full-length hSMN RNA. (A) Representative
polyacrylamide gel showing RT-PCR product obtained from hSMN
RNA exons 4-8. One-cell Tg(hSMN2)os38 embryos were injected
with 9, 15 or 18 ng of ISS-N1 MO. RNA samples were prepared at
3 dpf for RT PCR. (B) Quantification of the ratio of full-length
hSMN/hSMNΔ7 RNA from three separate experiments shown as
mean ± sd.
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mutant fish
Small changes in full-length SMN can alter disease phe-
notypes in patients and in animal models [20,21]. We
therefore asked whether the presence of the hSMN2
transgene and the presence of a small amount of hSMN
protein could extend survival of smn mutants, For these
experiments we utilized zebrafish smn stop mutation,
smnY262stop. We had previously shown that smnY262-
stop
-/- die at 12 dpf (range: 9-16 dpf) [12]. To determine
whether the modest increase in hSMN extended survival
of smnY262stop
-/- mutants, we analyzed survival of Tg
(hSMN2)os38;smnY262stop




+/- and embryos were heat shocked at 1
dpf and screened at 2 dpf for DsRed fluorescence indi-
cative of the transgene. DsRed positive embryos and
DsRed negative embryos were identified and monitored
over 23 days. Any larvae that died were kept and on day
23, all fish were genotyped to identify the smnY262-
stop
-/- larvae from both the positive and negative trans-
gene populations. We found that the hSMN2 transgene
slightly extended the survival of smnY262stop
-/- from an
average of 12 (9-16) to14.7 (10-17) dpf (p < 0.0001)
(Figure 6). This increase in survival is consistent with
the slight increase in full-length hSMN from the Tg
(hSMN2)os38 gene seen by Western blot (Figure 5). We
did not, however, see any difference in the survival of
Tg(hSMN2)os38; smnY262stop
-/- injected with the ISS-
N1 MO (n = 120 larvae) (data not shown). This is con-
sistent with our finding that the increase in full-length
hSMN in Tg(hSMN2)os38 ISS-NI MO injected embryos
was transient and gone by 7 dpf (data not shown).
These data suggest that this transient increase in hSMN
was not enough to affect later events such as survival.
hSMN2 rescues the presynaptic NMJ defect
We have shown that presynaptic terminals are present
in zebrafish smn mutants, but there is a decrease in SV2
protein at the NMJ [12]. Our hypothesis is that SV2 loss
at the NMJ is an indication that the synapse is becom-
ing compromised. To ask whether SV2 loss is observed
in Tg(hSMN2)os38;smn
-/- larvae, we analyzed SV2
expression (Figure 7). We crossed Tg(hSMN2);smnY262
stop
+/- to smnY262stop
+/- and larvae carrying the trans-
gene were identified by heat shock and raised to 11 dpf.
At this time they were genotyped and immunolabeled
with SV2 and a-bgt. In Tg(hSMN2)os38;smnY262
-/- at
11 dpf, SV2 and a-bgt were co-localized and no NMJ
defects were observed compared to smnY262stop
-/- lar-
vae that had an overall reduction in SV2 as compared to
wild-types (Figure 7A-B, F). Introduction of hSMN2,
however, rescued the SV2 reduction seen in homozy-
gous smn mutants (Figure 7C, F). We repeated the
immunolabeling at 14 dpf and observed SV2 defects
similar to those seen in the homozygous smn mutants
(Figure 7E, F). To quantify the NMJ defects, we plotted
the co-localization efficiency of the pre- and postsynap-
tic regions. These data are consistent with our previous
observation [12] indicating that when SMN levels are
low, presynaptic NMJ changes occur.
Discussion
Here we characterize the generation and characteriza-
tion of a zebrafish having both genetic components of
SMA; that is, a mutation in the endogenous smn gene
and the presence of the human SMN2 gene. We show
that hSMN2 is spliced correctly in zebrafish and that it
contributes a small amount of full-length hSMN. This
increase in SMN protein statistically improved survival,
albeit by only a few days, and rescued the presynaptic
NMJ defect for that same number of days. We also
show using the Tg(hSMN2) line that we can modulate
the amount of full-length hSMN RNA by disrupting an
intronic splicing silencer site with an antisense MO.
Thus, this model has utility both as a vertebrate model
of SMA and as a way to test approaches to increase
full-length SMN from the SMN2 gene in vivo.
Figure 5 hSMN protein in Tg(hSMN2) larvae. (A) Representative




brain (10 μg); Lane 2-4, wt, Tg(hSMN2)os38, and Tg(hSMN2)os38 +1 5
ng ISS-N1 MO zebrafish larvae collected at 3 dpf (150 μg of protein
per lane). The blot was probed with human SMN [18] and b-actin
monoclonal antibodies. (B) Quantification of hSMN band intensity
from two experiments shown as mean ± sd.
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transgene only increased survival by ~2 days is due to the
fact that it only increased full-length protein by a small
amount. Because we have multiple lines that all express
at low levels, this is not likely due to integration sites, but
more likely caused by the hSMN promoter not being very
efficient in zebrafish or human RNA not being translated
efficiently in zebrafish. To further increase the amount of
full-length SMN in this model, we can increase the copies
of the hSMN2 transgene by crossing in additional copies
of the hSMN2 g e n e .H o w e v e r ,i td o e sa p p e a rt h a tt h e
human SMN2 promoter is not very robust in zebrafish as
our highest expressing line (os38) has 30 copies of the
transgene and only a slight increase in SMN protein. It is
also possible that some of these copies are silenced [22].
Data from human patients and mouse models of SMA
show, however, that even slight increases in SMN
increase survival and decrease disease severity. This is
supported by data presented here showing that a slight
increase in protein can cause a corresponding increase in
survival and a delay in presynaptic defects.
In previous experiments, we showed that driving
hSMN cDNA only in motoneurons (using the zebrafish
hb9/mnx1 promoter) rescued the presynaptic NMJ
defect, but not survival [12]. It is not surprising that sur-
vival was not rescued since SMN is needed in all cells,
even at low levels, or the organism will die [23]. In the
model presented here, SMN present at low levels in all
cells extended survival and rescued the SV2 presynaptic
defect during that extension. However, before the fish
died, their SV2 decreased much as it did in mutants
lacking the transgene [12] (Figure 7). These data support
our earlier conclusion that low levels of SMN lead to
changes at the NMJ presynaptic terminal [12]. This is
also consistent with mouse models of SMA that show
poor presynaptic terminal differentiation [24], decreased
density of synaptic vesicles [25], and evidence of unoc-
cupied synapses [26]. Drosophila models also show evi-
dence of NMJ defects [11]. Thus, across species, low
levels of SMN result in NMJ defects.
These data show that we have generated a complete
genetic model of SMA in zebrafish. This is only the sec-
ond model organism where this has been accomplished.
Having this model in zebrafish complements the mouse
models and also provides the ability to perform different
types of experiments. For example, it is very standard in
zebrafish to generate genetics mosaics to address issues
of cell autonomy [27,28]. Since large numbers of
embryos can be collected, this system is also amenable
to drug screening [29]. Moreover, as we show here this
model can be used to quickly and easily test compounds
to determine their affect on hSMN2 splicing in vivo.
Methods
Zebrafish maintenance
Adult zebrafish and embryos were maintained by stan-
dard protocols [30]. All fish were maintained at tem-
peratures between 27 and 29°C. Zebrafish used for
making transgenics were on the *AB/LF background.
Characterization of the smnY262stop mutant has been
previously described [12].
Cloning and recombineering
Two 540 bp fragments (arms) from human PAC215p15
(AC004999) were amplified using PCR for recombineer-
ing [15]. These arms were complementary to sequences
Figure 6 hSMN2 extends the survival of smnY262stop
-/- fish. Survival was followed up to 23 dpf and a Kaplan-Meier plot was generated. Tg
(hSMN2)os38, purple line, n = 143; Tg(hSMN2)os38; smnY262stop
+/-, red line, n = 62; Tg(hSMN2)os38; smnY262stop
-/-, green line, n = 25;
smnY262stop
-/-, blue line, n = 40. The average survival was 12 dpf (range = 7-15 dpf) for smnY262stop
-/- larvae and 14.7 dpf (range = 10-17 dpf)
for Tg(hSMN2)os38; smnY262stop
-/- (p < 0.0001).
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The 5’ arm was amplified by PCR using forward primer:
5’AGTGAGCTCAAGCATTCTTATACACCACCC;
reverse primer: 5’GGACACGCGTTGTCAAAGATCA-
G A T A G T T Ga n dd i g e s t e dw i t hS a cIa n dM l uI .T h e
3’ arm was amplified using PCR forward primer:
5’ACTACGCGTGATCCTGTGGCTTCAATGTCAT;
reverse primer: 5’ CAGCAAGCTTCAGGATATGAT
CTCCATACAG and digested with Mlu I and Hind
III. These two digested PCR products were then triple
cloned into SacI and Hind III sites of the pBlue-
scriptSK (pBSK) vector which contained two Sce I
sites (gift from Dr. Bruce Appel) and referred to as
the pBSK arm vector. The EGFP from pEGFP-1 back-
bone (Clontech) was removed at Sal I and Not I sites
and replaced by DsRed. The last 0.6 kb of the zebra-
fish hsp70 promoter generated from the EcoR1 site
inside the full promoter [16] was amplified with
DsRed using primer forward 5’ATATAAGCTTACTG-
GAGGCTTCCAGAACAG and reverse 5’GCCTCGA
GCTTAAGATACATTGATGAGTTTG. The PCR
product was digested with Hind III and Xho I and
cloned into the pBluescript arm vector.
The entire fragment containing two Sce I sites, two
arms and 0.6 kb of the Hsp70-DsRed was amplified
using PCR with forward primer 5’TAAGGATCCCACG-
GAAACAGCTATGACC and reverse primer 5’ATAG-
GATCCCACGACGTTGTAAAACGACG. The entire
PCR product was digested with Bam HI and cloned into
pIndigoBac5 (Epicentre). This DNA plasmid was
digested with Mlu I and 5 ng of digested DNA was used
for transformation. One colony of PAC215p15 in
SW102 cells was grown overnight at 32°C in 3 ml cul-
ture containing kanamycine. The culture was diluted to
1% in 15 ml and grown at 32°C until it reached OD =
0.6 and then shaken at 42°C for 15 minutes. The culture
was chilled on ice for 10 minutes and washed twice in
ice-cold water. The cell pellet was eluted in 100 μlo f
water and used for electro transformation with the
above digested plasmid and spread onto cloramphenicol
agar plates and grown overnight at 32°C. Colonies were
cultured at 32°C and plasmids were screened for the
35.5 kb fragment by digesting with Bam HI.
Generation of transgenics
DNA injections were performed as described [31]. Plas-
mid DNA was prepared (Qiagen Plasmid Midi kit) and
diluted to 200 ng/μl in I-SceI buffer containing 10 mM
Tris-HCl, 1 mM dithiothreitol, 10 mM MgCl2,p H8 . 8 ,5
Units of SceI enzyme (New England Biolab) and 0.1%
phenol red. Sample was prepared fresh before each injec-
tion. DNA (200 ng/μl) was injected into embryos at the
early one-cell stage to 10% of the volume of the cell (~ 1
nl). Injected embryos were transferred into fish water
containing penicillin/streptomycin (Invitrogen) 1/100.
Injected fish (F0s) were heat shocked at 1 dpf at 37°C for
30 minutes and screened at 2 dpf. To increase the likeli-
hood that the transgene would go germline, only F0s
expressing DsRed in close to 100% of cells were kept and
grown to adulthood. Once they reached adulthood, F0s
were outcrossed to wild-type fish and the resulting F1s
Figure 7 Tg(hSMN2) rescues the NMJ defect in smn mutants.
Immunolabeling of presynaptic regions (SV2, red) and postsynaptic
regions (a-bgt, green) of (A) 11 dpf WT larvae (n = 10); (B) 11 dpf
smnY262stop
-/- larvae (n = 13); (C) 11 dpf Tg(hSMN2)os38;
smnY262stop
-/- larvae (n = 12); (D) 14 dpf WT larvae (n = 8) (E) 14
dpf Tg(hSMN2)os38; smnY262stop
-/- larvae (n = 12); Merge is the
overlay. (F) The coefficients of co-localization were plotted and the
means of each group were calculated. Tg(hSMN2)os38;
smnY262stop
-/- were significantly different compared to the
smnY262stop
-/- at 11 dpf (p < 0.0001). At 14 dpf, there was a
significant difference between the Tg(hSMN2)os38;smnY262stop
-/-
and wild types. Scale bar, 80 μm.
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F1s were grown to adulthood and outcrossed to generate
transgenic lines. F1s from the same F0 were kept as sepa-
rate lines since they could arise from transgene insertion
into different germ cells. Transgenic lines were desig-
nated as: Tg(hSMN2;0.6hsp70:DsRed) followed by the lab
designation (os for Ohio State) and a line number.
RNA extraction, RT PCR, and sequencing of SMN2
transcripts
Total RNA from zebrafish embryos and larvae was isolated
using Trizol reagent (Invitrogen) following the manufac-
turer’s protocol. RT-PCR was performed on 10 ng of total
RNA using a Quigen one-step RT-PCR kit. RNA from the
hSMN2 gene was amplified by human specific primers in
e x o n4a n d8a si nL ee ta l .[ 7 ] :5 ’-GTGAGAACTC-
CAGGTCTCCTGG-3’ and 5’-CTACAACACCCTTCT-
CACAG-3’. Human breast cancer cell line MCF10CA1a
w a su s e da sac o n t r o l( g i f tf r o mt h eH a il a b ) .P C Rp r o -
ducts were run on 8% polyacrylamide gel. Images were
captured by Gel Doc 2000 (Bio Rad). The images were
scanned and the intensity of the full-length hSMN and
hSMN7 bands were determined by Photoshop Element
5.0. The ratios of intensity of full-length hSMN and
hSMNΔ7 were reported.
For sequencing hSMN2 transcripts, RT-PCR was per-
formed on total RNA extracted from ten 3 dpf Tg
(hSMN2)os38 larvae using human specific primers in
e x o n4a n d8[ 7 ] .T h eP C Rp r o d u c tw a sr u no na1 %
agarose gel and the four bands excised and purified
using Qiagen gel extraction kit. Purified PCR products
were then cloned into PCR8/GW/Topo vector (Invitro-
gen) using PCR8/GW/Topo TA cloning kit (Invitrogen).
DNA plasmids were sequenced using primer M13F with
sequence GTAAAACGACGGCCAG. The sequencing
results were blasted to NCBI Reference Sequence:
NM_000344.3.
Quantitative PCR
DNA was extracted from adult fish fins using DNeasy
Tissue Kit (Qiagen). Quantitative PCR (qPCR) was per-
formed as described in Ramesh et al, 2010 [32]. The
hSMN2 transgene was detected with primers to amplify
intron2: SMN2F2 5’-GCGATAGAGTGAGACTCCATC
and SMN2R1 5’-GACATAGAGGTCTGATCTTTA
GCT. Fish b-actin Fp r i m e r s :5 ’-CATGAGACCACCTT
CAACTCC and fish b-actin R primer: 5’-TGAAAT-
CACTGCAAGCAAACTG were used to amplify the
endogenous b-actin gene.
D N Af r o ml o wa n dh i g hc o p ySMN2 transgenic mice
[3] and DNA from human breast cancer cell line
MCF10CA1a was used as a control. The mouse b-actin
gene was amplified using mouse b-actin F 5’-GTATG-
GAATCCTGTGGCATCC and mouse b-actin R 5’-
ATACAAGATGGTGAATGGTGAG primers. The
qPCR was performed on the iCycler (Bio-rad) with
IqSYBR Green Supermix (BioRad) containing 5 ng of
genomic DNA and 10 pmol of each primer. The data
was analyzed as described [32].
Antisense oligonucleotides injection
A morpholino directed against an intron splice silencer
(ISS-N1) site with sequence ATTCACTTTCA-
TAATGCTGG [18] was purchased from Gene Tools.
The stock was diluted to 2 mM in dH2O. One-cell
stage Tg(hSMN2)os38 embryos were injected with 9, 15
and 18 ng of the ISS-N1 MO using an MPPI-2 Pressure
Injector (Applied Scientific Instrumentation). Injection
of these three doses was repeated three times. At 3 dpf
total RNA from injected and uninjected zebrafish
embryos was isolated using Trizol reagent (Invitrogen)
following the manufacturer’s protocol. RT-PCR was per-
formed twice for each sample for a total 6 RT-PCR
reactions per treatment. The products were run on 8%
polyacrylamide gel and images were captured by Gel
D o c2 0 0 0( B i oR a d ) .T h ei m a g e sw e r es c a n n e da n dt h e
intensity of the full-length hSMN and hSMNΔ7 bands
were determined by Photoshop Element 5.0. The ratios
of intensity of full-length hSMN and hSMNΔ7 were
reported.
Survival assay and genotyping
T h es u r v i v a la s s a yw a sp e r f o r m e do np r o g e n yf r o m
crosses between heterozygote Tg(hSMN2)os38 and
smn262
+/- fish. Progeny from these crosses were heat
shocked at 1 dpf and screened at 2 dpf. Tg(hSMN2)os38
were fluorescent and kept for analysis. Those without a
D s R e ds i g n a lw e r ek e p ta st h ec o n t r o lg r o u p .B o t h
g r o u p sw e r er a i s e di nt h es a m en u r s e r ye n v i r o n m e n t .
The dead larvae were collected twice a day and frozen.
At 23 dpf, the remaining larvae were sacrificed and all
larvae, including those that died earlier, were then geno-
typed as described [12]. For each fish time of death, sur-
vival status, and classification were put into SPSS (SPSS
version 15; SPSS, Chicago, IL, USA). Kaplan-Meier sur-
vival tests were run to generate the survival curve and
p-values were calculated by the log-rank test.
Western blotting
Six zebrafish embryos (3 dpf) of wild-type, Tg(hSMN2)
os38 and Tg(hSMN2)os38 injected with 15 ng ISS-N1
MO were dissolved in 10 μl of blending buffer (62.6
mM Tris pH 6.8, 5 mM EDTA and 10% SDS) and
boiled for 10 minutes. The samples were then diluted
with an equal volume of loading buffer (100 mM Tris
pH 6.8, 4% SDS, 0.2% Bromophenol Blue, 20% glycerol
and 200 mM dithiothreitol), boiled for 2 minutes. The
whole amount of each sample from six embryos (~150
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+/+ mice [33] were resolved on a 12.5%
polyacrylamide gel. The gel was electrotransfered to the
Protran BA 83 Nitrocellulose membrane (Whatman).
Membranes were probed with mouse monoclonal anti-
bodies: human specific SMN-KH monoclonal antibody
[18] (1/20) or anti-actin (Santa Cruz) (1/5000). Signal
was detected with horseradish peroxidase-conjugated
goat anti-mouse antibody (1/5000) (Jackson ImmunoRe-
search Laboratories, Inc), ECL reagents and Amersham
Hyperfilm ECL (Amersham Bioscience). The images
were scanned from two separate experiments and the
intensity of the bands determined by Photoshop Ele-
ment 5.0 and reported as mean ± sd.
Immunofluorescence staining and confocal microscopy
Zebrafish larvae were anesthetized with tricain (Sigma,
A-5040). The head of each larva was removed for geno-
typing as described [12]. The body was fixed in 4% par-
aformaldehyde in PBS and 1% DMSO overnight at 4°C.
Larvae were then washed in 1XPBS for 10 minutes, dis-
tilled H2O for 10 minutes followed by a 15 minute incu-
bation at room temperature with -20°C Acetone.
Samples were then washed with distilled H2Of o r2 0
minutes. Postsynaptic regions were immunostained for 1
hour with a-bgt conjugated to Alexa Fluor 488 (Invitro-
gen) diluted 1/100 in PBDT buffer (1XPBS, 1% DMSO,
1% BSA, 0.5% TritonX-100) and 2.5% normal goat
serum as in [12]. Samples were washed for 10 minutes
5X in PBST (0.5% TritonX-100 in 1XPBS). Samples
were then incubated overnight at 4°C with presynaptic
antibody SV2 diluted 1/100 in PBDT buffer and 2.5%
normal goat serum. Samples were washed 5 × 10 min-
utes with PBST at room temperature and incubated
o v e r n i g h ta t4 ° Cw i t hA l e x aF luor 633 goat-anti mouse
IgG (Invitrogen) diluted 1/400 in PBDT and 2.5% nor-
mal goat serum. Samples were washed for 5 × 10 min-
utes in PBST, mounted on a slide with vectashield
(Vector Labs, Burlingame, CA, USA) and images were
captured with the Leica TCS SL scanning confocal
microscope system. Neuromuscular junction (NMJ) ana-
lysis was performed as described [12]. Changes in the
co-localization coefficients and log ratios of pre- and
postsynaptic only regions determined by NIH Image J
were analyzed using a one-tailed Mann-Whitney U test
(R 2.6.0; GNU project).
List of abbreviations
SMA: spinal muscular atrophy; SMN: survival motor neuron; α-bgt: α-
bungerotoxin; hpf: hours post fertilization; dpf: days post fertilization.
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